🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOral GLP-1 AgonistsOrforglipron liver safety profile — hepatic considerations Page 4

Orforglipron liver safety profile — hepatic considerations

MASHdoc_SA Thu, May 28, 2026 at 5:37 PM 16 replies 520 viewsPage 4 of 4
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Jun 3, 2026 at 12:39 AM#16
sophie_paris said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Second this. I had assumed I was the exception until I read this.

38 11julia.endo, JessicaM_2024, TomFromTexas and 35 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Jun 3, 2026 at 4:20 PM#17
Dr.RaviCardio said:
Say what you would expect to see if you were wrong, before you look.

That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

39 12MariaRD, AussieAnna, BethLabQueen and 36 others
Reply Quote Save Share Report
emily_PDX
Member
245
1,123
Nov 2024
Portland, OR
Jun 4, 2026 at 8:01 AM#18
Dr.RaviCardio said:
Say what you would expect to see if you were wrong, before you look.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Sending this to two other people who asked me the same thing last week.

40 13Dr.NateNeph, PharmD_Rodriguez, julia.endo and 37 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Jun 4, 2026 at 11:42 PM#19

Adding the clinical framing, because it changes how the question reads. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

41 14pete_nash, hank_denver, carlos_SATX and 38 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 5, 2026 at 3:24 PM#20

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Carry on.

13 11PurityPaulOR, MaxMetOK, MounjBrad and 10 others
Reply Quote Save Share Report

Similar Threads

Orforglipron Phase 3 ATTAIN-1 topline — oral non-peptide GLP-116 replies
Oral semaglutide 50mg (Rybelsus HD) — OASIS program results12 replies
Danuglipron BID dosing — Pfizer oral GLP-1 update7 replies
Oral vs injectable GLP-1: bioavailability and efficacy comparison5 replies
Orforglipron food interaction profile — no fasting requirement15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register